Wall Street is Counting Out the Biggest Breakthrough in Medicine – Here’s How to Make Their Mistake into Your Gain
When Wall Street overreacts and goes right, you can make a fortune by avoiding the noise and going in the opposite direction.
In the latest edition of wild overreactions, Cathie Wood, the top-notch ETF manager of Ark Investment Management, received some flak from The Wall Street Journal.
I’ll have more on that in just a bit and why it is totally off the mark.
But make no mistake. Wood has an uncanny eye for finding breakout stocks with a market-beating track record to prove it.
One particular feather in Wood’s cap is an ETF that she runs focusing on the cutting-edge field of genomics, a tech that basically didn’t exist just a decade ago.
Without genomics, we wouldn’t have been able to understand the structure of the coronavirus. Not only that, but the first two vaccines approved both relied on a hot new segment of genomics.
And this is an industry that is projected to multiply from $18.85 billion in 2019 to $82.60 billion in 2027, according to Fortune Business Insights. That’s more than 300% growth in less than a decade.
I’ll give you more details in a moment. But first, I want to point out the sizzling returns that Wood has amassed.
Over roughly the past year, Wood’s fund beat the market by a stunning 471%.